Profile data is unavailable for this security.
About the company
ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.
- Revenue in USD (TTM)378.00k
- Net income in USD-58.07m
- Incorporated2020
- Employees83.00
- LocationATAI Life Sciences NVWallstrasse 16Berlin 10179GermanyDEU
- Phone+49 8 921539035
- Fax+49 89 215390351
- Websitehttps://atai.life/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caribou Biosciences Inc | 33.11m | -123.44m | 187.95m | 158.00 | -- | 0.6054 | -- | 5.68 | -1.39 | -1.39 | 0.3763 | 3.44 | 0.0917 | -- | 15.61 | 209,576.00 | -34.17 | -- | -37.56 | -- | -- | -- | -372.78 | -- | -- | -1,231.11 | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| CytoDyn Inc | 0.00 | -51.32m | 197.79m | 9.00 | -- | -- | -- | -- | -0.0527 | -0.0527 | 0.00 | -0.1103 | 0.00 | -- | -- | 0.00 | -444.45 | -259.15 | -- | -- | -- | -- | -- | -232,918.20 | -- | -2.76 | -- | -- | -- | -- | 35.70 | -- | -- | -- |
| Vaxart Inc | 13.93m | -75.66m | 204.72m | 109.00 | -- | 2.56 | -- | 14.70 | -0.4707 | -0.4707 | 0.0861 | 0.3518 | 0.1178 | -- | 5.80 | 127,779.80 | -64.01 | -49.60 | -73.18 | -54.86 | -- | -- | -543.21 | -1,398.00 | -- | -226.73 | 0.0507 | -- | 6,796.26 | 12.15 | 23.47 | -- | 21.49 | -- |
| Gossamer Bio Inc | 95.84m | -80.85m | 206.12m | 135.00 | -- | 2.53 | -- | 2.15 | -0.3996 | -0.3996 | 0.434 | 0.3604 | 0.3453 | -- | -- | 709,940.80 | -29.13 | -57.43 | -34.41 | -64.38 | -- | -- | -84.36 | -- | -- | -7.07 | 0.7073 | -- | -- | -- | 21.61 | -- | -- | -- |
| MacroGenics Inc | 41.02m | -136.37m | 206.98m | 339.00 | -- | 3.58 | -- | 5.05 | -2.19 | -2.19 | 0.6583 | 0.9218 | 0.1619 | 6.62 | 6.51 | 120,997.00 | -53.82 | -37.76 | -67.56 | -45.53 | 79.37 | -- | -332.47 | -133.96 | 2.69 | -172.62 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
| ATAI Life Sciences NV | 378.00k | -58.07m | 208.07m | 83.00 | -- | 1.24 | -- | 550.45 | -0.3852 | -0.3852 | 0.0023 | 1.00 | 0.0016 | -- | 0.0331 | 4,554.22 | -24.68 | -- | -26.93 | -- | -- | -- | -15,320.63 | -- | -- | -90.71 | 0.0992 | -- | 34.76 | -- | 73.60 | -- | -- | -- |
| Fulcrum Therapeutics Inc | 81.63m | -20.23m | 214.66m | 76.00 | -- | 0.7821 | -- | 2.63 | -0.3507 | -0.3507 | 1.31 | 4.40 | 0.2746 | -- | 29.13 | 1,074,079.00 | -6.81 | -50.55 | -7.14 | -55.91 | -- | -- | -24.79 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
| Pyxis Oncology Inc | 16.15m | -59.20m | 215.73m | 51.00 | -- | 1.27 | -- | 13.36 | -1.26 | -1.26 | 0.3269 | 2.88 | 0.0842 | -- | -- | 322,920.00 | -30.87 | -- | -33.12 | -- | 97.06 | -- | -366.67 | -- | -- | -- | 0.0008 | -- | -- | -- | 38.87 | -- | -- | -- |
| Cabaletta Bio Inc | 0.00 | -89.98m | 218.84m | 136.00 | -- | 1.08 | -- | -- | -1.92 | -1.92 | 0.00 | 4.13 | 0.00 | -- | -- | 0.00 | -44.76 | -33.76 | -47.90 | -35.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.75 | -- | -- | -- |
| Codexis Inc | 60.89m | -76.36m | 220.58m | 174.00 | -- | 3.59 | -- | 3.62 | -1.09 | -1.09 | 0.8723 | 0.8665 | 0.3595 | 6.27 | 3.58 | 349,942.50 | -45.08 | -17.13 | -56.05 | -20.23 | 77.95 | 77.29 | -125.41 | -37.04 | 2.92 | -- | 0.3158 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
| Compass Therapeutics Inc. | 850.00k | -47.24m | 224.27m | 32.00 | -- | 1.54 | -- | 263.85 | -0.3573 | -0.3573 | 0.0064 | 1.06 | 0.0051 | -- | -- | 26,562.50 | -28.22 | -41.75 | -29.94 | -46.41 | -- | -- | -5,557.88 | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
| Omeros Corp | 0.00 | -199.92m | 227.73m | 198.00 | -- | -- | -- | -- | -3.32 | -2.35 | 0.00 | -2.15 | 0.00 | -- | -- | 0.00 | -45.24 | -55.51 | -58.74 | -70.10 | -- | -- | -- | -- | -- | -5.74 | 1.42 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
| XBiotech Inc | 0.00 | -35.01m | 228.47m | 94.00 | -- | 1.16 | -- | -- | -1.15 | -1.15 | 0.00 | 6.46 | 0.00 | -- | -- | 0.00 | -15.53 | 31.88 | -16.32 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0484 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| Nektar Therapeutics | 93.16m | -177.08m | 231.94m | 137.00 | -- | 2.91 | -- | 2.49 | -0.9007 | -0.9007 | 0.4747 | 0.4329 | 0.2224 | 2.16 | 73.61 | 679,978.10 | -42.28 | -31.02 | -48.54 | -34.63 | 59.22 | 78.04 | -190.09 | -372.21 | 4.90 | -18.76 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
Data as of Sep 19 2024. Currency figures normalised to ATAI Life Sciences NV's reporting currency: US Dollar USD
5.69%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Walleye Capital LLCas of 30 Jun 2024 | 2.76m | 1.65% |
| Morgan Stanley Investment Management, Inc.as of 30 Jun 2024 | 1.78m | 1.06% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 850.20k | 0.51% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 848.22k | 0.51% |
| Brown University Investment Officeas of 30 Jun 2024 | 718.50k | 0.43% |
| Two Sigma Investments LPas of 30 Jun 2024 | 717.13k | 0.43% |
| Millennium Management LLCas of 30 Jun 2024 | 648.19k | 0.39% |
| BlackRock Advisors (UK) Ltd.as of 30 Jun 2024 | 454.30k | 0.27% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 411.48k | 0.25% |
| Fiduciary Trust International LLCas of 30 Jun 2024 | 356.36k | 0.21% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
